摘要
在正常的细胞生理学,线粒体起着至关重要的作用,最近几年发现它们与众多疾病的发生有关。这两个角色的核心是在两种不同形态之间互换的能力:一个细长的相互链接型和支离破碎的离散表型——变化的过程分别是收线粒体融合与分裂蛋白的调控。在这篇综述中,我们专注于线粒体融合蛋白视神经萎缩蛋白1(OPA1)在心血管健康和疾病中的作用,我们探索其作为一个潜在治疗心血管和代谢疾病的目标。
关键词: 心血管疾病,裂变,融合,线粒体形态学,视神经萎缩蛋白1
Current Drug Targets
Title:OPA1 in Cardiovascular Health and Disease
Volume: 16 Issue: 8
Author(s): Niall Burke, Andrew R. Hall and Derek J. Hausenloy
Affiliation:
关键词: 心血管疾病,裂变,融合,线粒体形态学,视神经萎缩蛋白1
摘要: Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.
Export Options
About this article
Cite this article as:
Niall Burke, Andrew R. Hall and Derek J. Hausenloy , OPA1 in Cardiovascular Health and Disease, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150102113648
DOI https://dx.doi.org/10.2174/1389450116666150102113648 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Transcription Factor CHF1/Hey2 Regulates Specific Pathways in Serum Stimulated Primary Cardiac Myocytes: Implications for Cardiac Hypertrophy
Current Genomics Folding, Assembly, and Stability of Transmembrane Cytochromes
Current Chemical Biology High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Natriuretic Peptide Testing in Primary Care
Current Cardiology Reviews Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews The Importance of Lost Minerals in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Metabolic Therapy of Heart Failure
Current Pharmaceutical Design A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Subject Index to Volume 4
Current Gene Therapy